A Novel Influenza A (H1N1) Vaccine in Various Age Groups

2009341 citationsJournal Articlebronze Open Access

Authors

Fengcai Zhu · Jiangsu Provincial Center for Disease Control and Prevention

Hua Wang · Jiangsu Provincial Center for Disease Control and Prevention

Han-hua Fang · National Institutes for Food and Drug Control

Jian Guo Yang · Taizhou Municipal Hospital

Xiao Jun Lin

Xiaofeng Liang · Chinese Center For Disease Control and Prevention

Xuefeng Zhang · National Institutes for Food and Drug Control

Abstract

These data suggest that a single dose of 15 microg of hemagglutinin antigen without alum adjuvant induces a typically protective immune response in the majority of subjects between 12 and 60 years of age. Lesser immune responses were seen after a single dose of vaccine in younger and older subjects. (ClinicalTrials.gov number, NCT00975572).

Topics & Keywords

Influenza Virus Research Studies Respiratory viral infections research Viral Infections and Outbreaks Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 25, pp. 2414-2423

DOI: 10.1056/nejmoa0908535

Field-Weighted Citation Impact: 42.93